In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Generation Bio Co’s stock clocked out at $0.38, up 1.67% from its previous closing price of $0.38. In other words, the price has increased by $1.67 from its previous closing price. On the day, 0.77 million shares were traded.
Ratios:
To gain a deeper understanding of GBIO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.43 and its Current Ratio is at 8.43. In the meantime, Its Debt-to-Equity ratio is 1.19 whereas as Long-Term Debt/Eq ratio is at 1.07.
On November 08, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 10 ’25 when Quinn Anthony G. bought 125,791 shares for $0.96 per share. The transaction valued at 120,759 led to the insider holds 214,286 shares of the business.
Quinn Anthony G. bought 85,000 shares of GBIO for $82,450 on Jan 13 ’25. The Director now owns 299,286 shares after completing the transaction at $0.97 per share. On Jul 01 ’24, another insider, Paone Antoinette, who serves as the CHIEF OPERATING OFFICER of the company, sold 6,719 shares for $2.74 each. As a result, the insider received 18,410 and left with 13,807 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.05 while its Price-to-Book (P/B) ratio in mrq is 0.35.
Stock Price History:
Over the past 52 weeks, GBIO has reached a high of $3.65, while it has fallen to a 52-week low of $0.32. The 50-Day Moving Average of the stock is -3.65%, while the 200-Day Moving Average is calculated to be -70.06%.
Shares Statistics:
A total of 67.01M shares are outstanding, with a floating share count of 45.82M. Insiders hold about 31.65% of the company’s shares, while institutions hold 54.54% stake in the company.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.26 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.97 and -$0.97 for the fiscal current year, implying an average EPS of -$0.97. EPS for the following year is -$0.75, with 3.0 analysts recommending between -$0.17 and -$1.26.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $2.51M. It ranges from a high estimate of $4.1M to a low estimate of $155k. As of the current estimate, Generation Bio Co’s year-ago sales were $4.09MFor the next quarter, 5 analysts are estimating revenue of $2.49M. There is a high estimate of $4M for the next quarter, whereas the lowest estimate is $155k.
A total of 6 analysts have provided revenue estimates for GBIO’s current fiscal year. The highest revenue estimate was $20.8M, while the lowest revenue estimate was $8.7M, resulting in an average revenue estimate of $14.94M. In the same quarter a year ago, actual revenue was $19.89M
